The Ministry of Economic Affairs staged the 2024 Smart Healthcare Summit June 25 in Taipei City, highlighting the government’s commitment to raising Taiwan’s profile in intelligent medicine.
According to the MOEA, over 500 participants attended the forum, including representatives from U.S.-headquartered Medtronic, Microsoft and Cytiva; France-based Sanofi; and AstraZeneca’s Taiwan branch. Attendees explored current trends and the latest clinical applications with the goal of creating new business opportunities through interdisciplinary global perspectives.
Medicine and information and communications technology are among Taiwan’s most powerful industries, and artificial intelligence is key to integrating the two areas, the MOEA said. Taiwan boasts a comprehensive biomedicine industry supply chain, with extensive research capacity, highly experienced technological and medical talent, multiple clinical trial centers, rich medical data, global standards and robust patent protection, the ministry said, adding that all these factors make the country an ideal incubator for AI medical applications.
The MOEA has been collaborating with German pharmaceutical company Merck since 2018, initiating a new era of biomedical research in Taiwan, the ministry said. This was followed in 2019 with a cooperative pact inked with Johnson & Johnson’s Janssen Pharmaceuticals and the Future Healthcare Laboratory launched in partnership with AstraZeneca in 2020 to promote exchanges among domestic startups, it added.
To continue expanding links between Taiwan’s smart health care sector and international industry leaders, the MOEA will lead a group of domestic delegates to participate in an upcoming Medical Design & Manufacturing trade show in the U.S. and the MEDICA trade fair in Europe, the ministry concluded. (POC-E)
Write to Taiwan Today at ttonline@mofa.gov.tw
from Taiwan Today – Top News